D
D Apter
Researcher at University of Oulu
Publications - 17
Citations - 4214
D Apter is an academic researcher from University of Oulu. The author has contributed to research in topics: Vaccine efficacy & Cervical cancer. The author has an hindex of 9, co-authored 17 publications receiving 3997 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Jorma Paavonen,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,S R Skinner,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Franz X. Bosch,David Jenkins,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +26 more
TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.
Journal ArticleDOI
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen,David Jenkins,F. Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Newton Sérgio de Carvalho,S. Rachel Skinner,Diane M. Harper,James Hedrick,Unnop Jaisamrarn,Genara Limson,Marc Dionne,Wim Quint,Bart Spiessens,Pascal Peeters,Frank Struyf,Susan L. Wieting,Matti Lehtinen,Gary Dubin +23 more
TL;DR: The adjuvanted HPV16/18 vaccine showed prophylactic efficacy against cervical intraepithelial neoplasia (CIN) 2+ associated with HPV16 or HPV18 and thus could be used for cervical cancer prevention.
Journal ArticleDOI
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial
Helena von Hertzen,Gilda Piaggio,Alexandre Peregoudov,Juhong Ding,Junling Chen,Si Song,Gyorgy Bartfai,Ernest Hung Yu Ng,Kristina Gemzell-Danielsson,Amindavaa Oyunbileg,S. C. Wu,Wei-yu Cheng,Frank Lüdicke,Alenka Pretnar-Darovec,Rosemary Kirkman,Suneeta Mittal,Archil Khomassuridze,D Apter +17 more
TL;DR: The three regimens studied are very efficacious for emergency contraception and prevent a high proportion of pregnancies if taken within 5 days of unprotected coitus, and most women menstruated within 2 days of the expected date.
Journal ArticleDOI
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler,Xavier Castellsagué,Suzanne M. Garland,Anne Szarewski,Jorma Paavonen,Paulo Naud,Jorge Salmerón,Song Nan Chow,D Apter,Henry C Kitchener,Julio Cesar Teixeira,S. Rachel Skinner,Unnop Jaisamrarn,Genara Limson,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,F. Xavier Bosch,Diane M. Harper,Warner K. Huh,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Gary Dubin,Matti Lehtinen +26 more
TL;DR: Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against four oncogenic non-vaccine HPV types-HPV-33, HPV-31, HPV -45, and HPV-51-in different trial cohorts representing diverse groups of women.
Journal ArticleDOI
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.
Anne Szarewski,Willy Poppe,Willy Poppe,S R Skinner,Cosette M. Wheeler,Jorma Paavonen,Paulo Naud,Jorge Salmerón,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Franz X. Bosch,Diane M. Harper,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +27 more
TL;DR: In women with no evidence of current or previous HPV‐16/18 infection (DNA negative and seronegative), VE was 90.3% (96.1% confidence interval: 87.3–92.6) against 6‐month persistent infection (PI), and in women who were DNA positive for one vaccine type, the vaccine was efficacious against the other vaccine type.